Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor.

@article{Pescovitz2005DaclizumabHM,
  title={Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor.},
  author={Mark D. Pescovitz},
  journal={Expert review of clinical immunology},
  year={2005},
  volume={1 3},
  pages={337-44}
}
Daclizumab is a humanized antibody that binds to the alpha-chain of the interleukin-2 receptor and blocks the action of interleukin-2. It is approved for the prevention of organ allograft rejection using five 1 mg/kg doses every second week, starting at the time of transplant. Since approval, activity has primarily focused on the efficacy of shorter courses… CONTINUE READING